Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus (Q38771936)

6 September 2017

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus (English)

1 reference

systemic lupus erythematosus

6 September 2017

0 references

author name string

Colin Thorbinson

1

1 reference

6 September 2017

Louise Oni

2

1 reference

6 September 2017

Eve Smith

3

1 reference

6 September 2017

Angela Midgley

4

1 reference

6 September 2017

Michael W Beresford

5

1 reference

6 September 2017

12 March 2016

1 reference

6 September 2017

1 reference

6 September 2017

18

1 reference

6 September 2017

3

1 reference

6 September 2017

181-195

1 reference

https://scigraph.springernature.com/pub.10.1007/s40272-016-0170-8

6 September 2017

0 references

cites work

Ethnic differences in pediatric systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Prevalence and burden of pediatric-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Adding to complexity: comorbidity in paediatric rheumatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Biologics in SLE: towards new approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

21 January 2018

Pathogenesis of lupus

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Immune Interferon in the Circulation of Patients with Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Microarray analysis of interferon-regulated genes in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The development of genome-wide association studies and their application to complex diseases, including lupus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The origin and properties of extracellular DNA: from PAMP to DAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Common variable immunodeficiency in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

New insights into the pathogenesis and management of lupus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

T cells as therapeutic targets in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

PReS-FINAL-2356: A comparison of the American college of rheumatology and the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus using data from the uk juvenile systemic lupus erythematosus co

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Unmet medical needs in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Toll-like receptors and innate immune responses in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Therapy: Hydroxychloroquine in SLE: old drug, new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Glucocorticoid use and abuse in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Prednisone, lupus activity, and permanent organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Intermittent intravenous cyclophosphamide therapy for lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

BAFF AND APRIL: a tutorial on B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Challenges and opportunities in SLE clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Methodology of clinical trials for rare diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

First appearance and location of catecholaminergic cells during experimental arthritis and elimination by chemical sympathectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-016-0170-8

Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients

21 January 2018

1 reference

12 December 2020

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

1 reference

12 December 2020

Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?

1 reference

12 December 2020

Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus.

1 reference

12 December 2020

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

12 December 2020

The history of antimalarials.

1 reference

12 December 2020

Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus

1 reference

12 December 2020

Expression of Toll-like receptors and their detection of nuclear self-antigen leading to immune activation in JSLE

1 reference

12 December 2020

Lupus nephritis: toll the trigger!

1 reference

12 December 2020

Depletion of B cells in murine lupus: efficacy and resistance

1 reference

12 December 2020

Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

1 reference

12 December 2020

Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

12 December 2020

Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus

1 reference

12 December 2020

Rituximab therapy for childhood-onset systemic lupus erythematosus

1 reference

12 December 2020

The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison

1 reference

12 December 2020

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

12 December 2020

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

12 December 2020

Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis

1 reference

12 December 2020

10.1007/S40272-016-0170-8

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference